STAT23 天
Axsome to send Alzheimer’s disease drug to FDA, despite mixed Phase 3 results
Axsome Therapeutics is moving ahead with plans to submit its Alzheimer’s disease treatment for Food and Drug Administration approval despite mixed results from two new clinical trial readouts.
Strong Financial Performance and Promising Future: Axsome Therapeutics Receives Buy Rating ...
Axsome Therapeutics (AXSM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram ...
Taiwan News22 天
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program ...
Axsome plans to submit an NDA for AXS-05 in Alzheimer’s disease agitation to the FDA in the second half of 2025, based on the efficacy and safety data from the above controlled and long-term studies.
H.C. Wainwright Reiterates Buy Rating on Axsome Shares
H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a ...
Benzinga.com21 天
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
Further, AXS-05 reduced the worsening of overall Alzheimer's disease severity compared to the placebo. Also Read: Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In ...
Nasdaq22 天
Analysts see buying opportunity as Axsome slips on mixed Alzheimer’s studies
AXS-05 was safe and well tolerated in both controlled studies. Axsome plans to submit an NDA for AXS-05 in Alzheimer’s disease agitation to the FDA in the second half of 2025, based on the ...
Yahoo Finance21 天
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 (dextromethorphan-bupropion) in Alzheimer's disease agitation.
来自MSN22 天
Axsome Therapeutics Stock Tumbles As Alzheimer's Studies Reveal Mixed Results: Retail ...
“Axsome plans to submit an NDA for AXS-05 in Alzheimer’s disease agitation to the FDA in the second half of 2025, based on the efficacy and safety data from the above controlled and long-term ...
Business Insider22 天
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program ...
Axsome plans to submit an NDA for AXS-05 in Alzheimer’s disease agitation to the FDA in the second half of 2025, based on the efficacy and safety data from the above controlled and long-term ...
Benzinga.com22 天
STAT+: Axsome to send Alzheimer's disease drug to FDA, despite mixed Phase 3 results
Axsome Therapeutics is moving ahead with plans to submit its Alzheimer’s disease treatment for Food and Drug Administration approval despite mixed results from two new clinical trial readouts.
Stockhouse23 天
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program ...
Axsome plans to submit an NDA for AXS-05 in Alzheimer’s disease agitation to the FDA in the second half of 2025, based on the efficacy and safety data from the above controlled and ...
Reuters22 天
Axsome to seek approval for Alzheimer's-related agitation drug despite mixed data
Dec 30 (Reuters) - Axsome Therapeutics (AXSM.O), opens new tab said on Monday it would seek marketing approval next year for its oral drug to treat agitation in patients with Alzheimer's disease ...